Latest Conference Articles

Jonathan Silverberg, MD, PhD, MPH, shares pearls from the ADvocate1 and 2 trials examining the use of lebrikizumab for AD.

Jonathan Silverberg, MD, PhD, MPH, talks about therapies used for AD, including nemolizumab.

Researchers reveal the resilience of Cutibacterium acnes in the skin microbiome post-laser treatments, suggesting its beneficial roles in skin health and aging.

A new study highlights the significant long-term improvements in lesions and scarring of a clindamycin phosphate 1.2%, adapalene 0.15%, and benzoyl peroxide 3.1% formulation.

Recent posters at SID revealed significant increases in psoriasis and cellulitis cases in the US, highlighting urgent needs for prevention and treatment strategies.

Thiamidol emerges as a promising treatment for hyperpigmentation, showcasing superior efficacy and safety compared to traditional options like hydroquinone.

GLP-1 receptor agonists show promise in reducing cardiovascular risks for patients with chronic inflammatory skin diseases like psoriasis and atopic dermatitis.

Biologics significantly lower cardiovascular risks in psoriasis patients on statins, highlighting their dual benefits for skin and heart health.

Scott Batty, MD, and Chris VanDeusen, PhD, provided insights on AX-158's phase 2a results, presented at the SID Annual Meeting.

Recludix Pharma unveils a groundbreaking BTK SH2 inhibitor, showcasing superior selectivity and efficacy for chronic spontaneous urticaria treatment at SID 2025.

Extended oral corticosteroid therapy in patients with atopic dermatitis significantly increases cardiovascular and thrombotic risks, urging careful treatment evaluations.

Researchers reveal TRIV-509, a novel monoclonal antibody, shows promise in rapidly improving atopic dermatitis by restoring skin barrier integrity and reducing inflammation.

Johnson & Johnson's icotrokinra shows promising results in treating moderate plaque psoriasis, especially in challenging areas like the scalp and genitals.

The promising safety and efficacy results were presented at the Society for Investigative Dermatology 2025 Annual Meeting.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of May.

Discover how the RAD conference in Nashville enhances atopic dermatitis care, featuring expert insights and patient-focused strategies for clinicians.

Dermatology undergoes rapid transformation with new therapies, but faces challenges in payment reform, certification awareness, and balancing technology with patient care.

Paller discusses the promising phase 3 trial SELVA trial results for Qtorin 3.9% rapamycin gel, an investigative treatment for microcystic lymphatic malformations.

From our April issue: Unlock exclusive AAD 2025 insights from top dermatology experts—what you missed and what’s next.

Raj Chovatiya, MD, PhD, MSCI, reviews the benefits of Revolutionizing Atopic Dermatitis as a disease-specific conference.

A new subgroup analysis revealed higher rates of clear or almost clear skin at week 16 vs placebo with a favorable safety profile.

Get a glimpse of the cutting-edge atopic dermatitis research, breakthroughs, and insights to be presented at the 7th RAD Annual Meeting, June 6-7, 2025.

Dermatology Times has compiled a list of dermatological meetings taking place during the month of April.

Asha Patel Shah, MD, MBA, FAAD, discusses recent research on retinol and retinoid bioactivity when layered with moisturizers highlighted at AAD 2025.

Discover the latest research from the AAD poster hall, compiled in one place for dermatology professionals.

Explore a comprehensive roundup of the most important AAD late breakers, all in one place – key insights from the latest dermatology research.

Catch up on all coverage from the 2025 American Academy of Dermatology Annual Meeting held in Orlando, Florida, March 7-11.

Christopher Bunick, MD, PhD, shares concluding remarks with colleagues at AAD 2025.